Concorde Asset Management’s BioTelemetry, Inc. BEAT Stock Holding History

Concorde Asset Management’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,397	Closed	-$356K	–	227
2019 Q2	$356K	Sell	7,397 -934	-11%	-$49.1K	0.21%	136
2019 Q1	$522K	Buy	+8,331	New	+$572K	0.34%	99
2017 Q4	–	Sell	-35,813	Closed	-$1.18M	–	165
2017 Q3	$1.18M	Buy	35,813 +10,799	+43%	+$374K	1.02%	26
2017 Q2	$837K	Buy	25,014 +15,180	+154%	+$453K	1.13%	17
2017 Q1	$285K	Buy	+9,834	New	+$244K	0.47%	78

Other funds holding BEAT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Concorde Asset Management's BEAT Position: Q3 2019 in Review

Concorde Asset Management sold out of BioTelemetry, Inc. (BEAT) in Q3 2019, closing a stake of 7,397 shares — an estimated $356K sold.

Concorde Asset Management first reported a position in BEAT in Q1 2017 and held it in 5 quarters. The position peaked at $1.18M in Q3 2017. 219 funds tracked by Wall St. Rank hold BEAT as of Q3 2019.

Concorde Asset Management reported no remaining BioTelemetry, Inc. position as of Q3 2019 after selling out during the quarter.
Concorde Asset Management sold 7,397 BioTelemetry, Inc. shares in Q3 2019, an estimated $356K.
Concorde Asset Management first reported a position in BioTelemetry, Inc. in Q1 2017 and held it in 5 quarters.
Concorde Asset Management's BioTelemetry, Inc. position peaked at $1.18M in Q3 2017.
219 funds tracked by Wall St. Rank held BioTelemetry, Inc. as of Q3 2019.

Based on Concorde Asset Management's 13F filing for Q3 2019, filed 28 Oct 2019.